Get 40% Off
🤑 This hedge fund gained 26.16% in the last month. Get their top stocks with our free stock ideas tool.See stock ideas

BioNTech takes a long fall on Pfizer outlook: 5 big analyst cuts

Published 10/16/2023, 11:58 PM
© Reuters
KBH
-
CMI
-
CCI
-
JD
-
BNTX
-

Investing.com — Here is your Pro Recap of the biggest analyst cuts you may have missed today: downgrades at Cummins, JD.com, BioNTech, Crown Castle, and KB Home.

InvestingPro subscribers got this news first. Never miss another market-moving headline.

BioNTech slashed at HSBC on lower COVID product sales forecast

HSBC downgraded BioNTech (NASDAQ:BNTX) to Hold from Buy after Pfizer 's (NYSE:PFE) lowered sales projections for its COVID vaccine and treatment were worse than some analysts had anticipated.

HSBC also cut BioNTech's price target to $111.00 from $124.00. Shares of the company, whose fortunes are tied to vaccine-related profit-sharing payments from Pfizer, were recently plunging 6% to $97.39.

Cummins cut to Underweight at JPMorgan

Cummins (NYSE:CMI) was downgraded by JPMorgan to Underweight from Neutral and cut its price target to $255.00 from $270.00, as reported in real time on InvestingPro.

The company is set to report its Q3/23 earnings on Nov 2. Street estimates stand at $4.76 for EPS and $8.21 billion for revenues.

Shares dipped on the downgrade in the premarket, but were up fractionally in recent regular-session trading at $228.49.

JD.com receives another downgrade

JD.com (NASDAQ:JD) was cut by Bernstein to Market Perform from Outperform, with the price target slashed to $31.00 from $55.00.

The analysts highlighted the stock's decline this year, which intensified after the company's weaker-than-expected trajectory for the remainder of 2023. With the company's struggles now evident to most, and despite it citing conservatism for its growth outlook, Bernstein remained skeptical of JD’s turnaround potential, especially given its vague strategies and limited growth expectations.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

This follows a pair of downgrades last week: Morgan Stanley cut the company to Equalweight from Overweight, setting a price target at $33.00, down from $55.00, and Macquarie moved to Neutral from Outperform, with a revised price target of $32.00 (from $52.00).

Still, shares were lately up 1.9% to $27.56.

InvestingPro | Know Market Moves

Two more downgrades

RBC Capital downgraded Crown Castle International (NYSE:CCI) to Sector Perform from Outperform and cut its price target to $100.00 from $125.00.

The rating change was driven by concerns over near-term catalysts for the stock’s valuation, uncertainties about dividend growth compared to net leverage, and questions regarding the rate of small cell/fiber growth.

The company is set to report its Q3/23 earnings on Oct 18, after the market close.

Shares were off fractionally to $94.29 in recent trading.

Goldman Sachs downgraded KB Home (NYSE:KBH) to Neutral from Buy and cut its price target to $48.00 from $54.00.

Shares took a hit in the premarket, but were recently ticking only marginally lower at $43.77.

***

Amid whipsaw markets and a slew of critical headlines, seize on the right timing to protect your profits: Always be the first to know with InvestingPro.

InvestingPro | Be The First To Know

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.